Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.68 |
| ▸ | HPGD | P15428 | 6/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.68 |
| ▸ | RECQL | P46063 | 1/20 | 0.68 |
| ▸ | RAB9A | P51151 | 8/20 | 0.63 |
| ▸ | NPC1 | O15118 | 7/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.63 |
| ▸ | TP53 | P04637 | 3/20 | 0.63 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.61 |
| ▸ | THRB | P10828 | 3/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.60 |
| ▸ | STAT1 | P42224 | 1/20 | 0.60 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.57 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.57 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.57 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.57 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.57 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.57 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29197994 | 0.87 | ACR (0.60) | MAPTHPGDALDH1A1RAB9ANPC1 | |
| SCHEMBL20507141 | 0.85 | HPGD (0.75) | MAPTHPGDALDH1A1RECQLRAB9A | |
| SCHEMBL15468406 | 0.85 | SMPD1 (0.70) | MAPTHPGDRAB9ANPC1SMN1; SMN2 | |
| SCHEMBL1686290 | 0.85 | ACR (0.54) | MAPTHPGDALDH1A1RECQLRAB9A | |
| SCHEMBL1686347 | 0.84 | POLB (0.66) | MAPTHPGDALDH1A1SMN1; SMN2TP53 | |
| SCHEMBL27237216 | 0.84 | ACR (0.58) | MAPTHPGDALDH1A1SMN1; SMN2TP53 | |
| SCHEMBL1686391 | 0.84 | TP53 (0.62) | MAPTRAB9ANPC1SMN1; SMN2TP53 | |
| SCHEMBL1686476 | 0.84 | MAPT (0.72) | MAPTALDH1A1RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL16112022 | 0.84 | ACR (0.53) | MAPTHPGDALDH1A1RECQLRAB9A | |
| SCHEMBL768649 | 0.84 | ACR (0.63) | MAPTHPGDALDH1A1RAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115716822-B | Application of benzimidazolyl isoxazoles in preparation of medicines related to multiple myeloma | 徐州医科大学 | 2025-05-16 | — | — | CN | disclosed |
| CN-117417334-A | Azole derivative containing isoxazole structure, and preparation method and application thereof | 沈阳药科大学 | 2024-01-19 | — | — | CN | disclosed |
| CN-115716822-A | Application of benzimidazolyl isoxazole compound in preparation of medicines related to multiple myeloma | 徐州医科大学 | 2023-02-28 | — | — | CN | disclosed |
| US-9150563-B2 | Nitrogen-containing aromatic heterocyclyl compound | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2015-10-06 | — | — | US | disclosed |
| US-20140187592-A1 | NITROGEN-CONTAINING AROMATIC HETEROCYCLYL COMPOUND | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2014-07-03 | — | — | US | disclosed |
| US-8648103-B2 | Nitrogen-containing aromatic heterocyclyl compound | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2014-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140187592-A1 | NITROGEN-CONTAINING AROMATIC HETEROCYCLYL COMPOUND | NPR1, NPR3, NPC1 | MAPT 4122/4885HPGD 1638/4885ALDH1A1 1307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.